EnteroMedics Inc. Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients

ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc., (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that the Food and Drug Administration (FDA) has granted approval for the expansion of its pivotal clinical trial, known as the EMPOWER Study, from 220 patients to 300 patients. Full enrollment in the EMPOWER Study is expected in the first half of 2008, consistent with previous projections, despite expansion of the study.

Back to news